Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Toulon – page 10

151 clinical trials in Toulon, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Toulon at a glance
151
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

151 trials in Toulon

Open in trial search

Non-small cell lung cancer+2

Not recruiting

Study of Niraparib and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer

Not recruiting

Study on Alectinib and Durvalumab for Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Hypertension

Not recruiting

Study on Baxdrostat for Reducing Blood Pressure in Patients with Uncontrolled or Resistant Hypertension

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Squamous cell carcinoma of head and neck

Not recruiting

Study on Xevinapant and Radiotherapy for High-Risk Head and Neck Cancer Patients Unable to Take High-Dose Cisplatin

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Xevinapant
  • Sponsor:Merck Healthcare KGaA

Non-small cell lung cancer stage IV+2

Not recruiting

Study comparing brigatinib alone versus brigatinib with carboplatin and pemetrexed combination as first treatment for patients with advanced ALK-positive lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Brigatinib
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Non-small cell lung cancer

Not recruiting

Study on Atezolizumab with Platinum-Based Chemotherapy for Patients with Early-Stage Resectable Non-Small Cell Lung Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Giant cell arteritis

Not recruiting

Comparing Methotrexate and Tocilizumab for Treating Giant Cell Arteritis in Patients: A Study on Effectiveness and Safety

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Folic Acid
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Non-small cell lung cancer+3

Not recruiting

Study on Chemotherapy with Paclitaxel, Cisplatin, and Carboplatin for Patients with Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Non-small cell lung cancer

Not recruiting

Study of Farletuzumab Ecteribulin for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Farletuzumab Ecteribulin
  • Sponsor:Bristol Myers Squibb International Corporation

Non-small cell lung cancer

Not recruiting

Study on Atezolizumab for Patients with Non-Small Cell Lung Cancer After Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Hidradenitis

Not recruiting

Study on the Long-Term Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
  • Sponsor:Incyte Corp.

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Toulon

What the registry says about research in the country

01 Oncology - Lung Cancer Research

Extensive clinical trials focusing on non-small cell lung cancer treatments, including innovative combination therapies and immunotherapy approaches. Multiple studies evaluating novel drug combinations to improve patient outcomes.

  • Advanced NSCLC Treatments
  • Immunotherapy Combinations
  • Post-Surgery Therapies

Research spans various disease stages and includes both early-stage and metastatic cancer treatments.

02 Hematology & Blood Disorders

Studies investigating treatments for chronic lymphocytic leukemia and blood-related conditions. Research includes evaluation of novel drug combinations and targeted therapies.

  • Leukemia Treatments
  • Blood Cancer Therapies
  • Lymphoma Management

Focus on improving treatment outcomes for previously untreated patients with coexisting conditions.

03 Cardiovascular Research

Investigations into stroke prevention and treatment of thrombotic conditions. Studies evaluating new anticoagulants and therapeutic approaches for various cardiovascular conditions.

  • Thrombosis Management
  • Heart Failure Treatments
  • Stroke Prevention Strategies

Clinical trials examining innovative treatments for atrial fibrillation and deep vein thrombosis.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.